Biomea Fusion/$BMEA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Biomea Fusion
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
Ticker
$BMEA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
79
ISIN
US09077A1060
Website
Biomea Fusion Metrics
BasicAdvanced
$96M
-
-$3.54
-0.08
-
Price and volume
Market cap
$96M
Beta
-0.08
52-week high
$12.22
52-week low
$1.29
Average daily volume
4.1M
Financial strength
Current ratio
2.255
Quick ratio
1.81
Long term debt to equity
22.622
Total debt to equity
27.585
Profitability
EBITDA (TTM)
-130.927
Management effectiveness
Return on assets (TTM)
-74.21%
Return on equity (TTM)
-156.81%
Valuation
Price to book
2.21
Price to tangible book (TTM)
2.21
Price to free cash flow (TTM)
-0.539
Free cash flow yield (TTM)
-185.65%
Free cash flow per share (TTM)
-313.75%
Growth
Earnings per share change (TTM)
-0.62%
3-year earnings per share growth (CAGR)
24.20%
What the Analysts think about Biomea Fusion
Analyst ratings (Buy, Hold, Sell) for Biomea Fusion stock.
Biomea Fusion Financial Performance
Revenues and expenses
Biomea Fusion Earnings Performance
Company profitability
Biomea Fusion News
AllArticlesVideos
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)
GlobeNewsWire·2 weeks ago
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates
GlobeNewsWire·3 weeks ago
Biomea Fusion Shares Fall After Pricing Underwritten Public Offering
Market Watch·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Biomea Fusion stock?
Biomea Fusion (BMEA) has a market cap of $96M as of July 08, 2025.
What is the P/E ratio for Biomea Fusion stock?
The price to earnings (P/E) ratio for Biomea Fusion (BMEA) stock is 0 as of July 08, 2025.
Does Biomea Fusion stock pay dividends?
No, Biomea Fusion (BMEA) stock does not pay dividends to its shareholders as of July 08, 2025.
When is the next Biomea Fusion dividend payment date?
Biomea Fusion (BMEA) stock does not pay dividends to its shareholders.
What is the beta indicator for Biomea Fusion?
Biomea Fusion (BMEA) has a beta rating of -0.08. This means that it has an inverse relation to market volatility.